Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZ compound-University of Alabama at Birmingham-non-alcoholic steatohepatitis-non-alcoholic fatty liver disease
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The AZ compound is a novel pharmaceutical agent developed by AstraZeneca that was evaluated in a Phase IIa clinical trial (NCT02348489) sponsored by the University of Alabama at Birmingham. The study was designed as a randomized, double-blinded, placebo-controlled trial to assess the efficacy and safety of the compound in subjects with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD). The primary objective was to determine if the drug could decrease liver fat content compared to a placebo over a 12-week treatment period. The compound was administered orally at a total daily dose of 800 mg, divided into two 400 mg doses taken in the morning and evening. However, the clinical development for this specific indication was terminated by AstraZeneca due to a change in their clinical development strategy for the compound.
- Other names
- AZ compound-University of Alabama at Birmingham-non-alcoholic steatohepatitis-non-alcoholic fatty liver disease
Beyond the preview
Go deeper on AZ compound-University of Alabama at Birmingham-non-alcoholic steatohepatitis-non-alcoholic fatty liver disease.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZ compound-University of Alabama at Birmingham-non-alcoholic steatohepatitis-non-alcoholic fatty liver disease.